References
Sethi S, Fervenza FC (2012) Membranoproliferative glomerulonephritis-a new look at an old entity. N Engl J Med 366:1119–1131
Bomback AS, Santoriello D, Avasare RS, Regunathan-Shenk R, Canetta PA, Ahn W, Radhakrishnan J, Marasa M, Rosenstiel PE, Herlitz LC, Markowitz GS, D’Agati VD, Appel GB (2018) C3 glomerulonephritis and dense deposit disease share a similar disease course in a large United States cohort of patients with C3 glomerulopathy. Kidney Int 93:977–985
Gertz MA, Kyle RA (1991) Secondary systemic amyloidosis: response and survival in 64 patients. Medicine 70:246–256
Pretel M, Marquès L, España A (2014) Drug-induced lupus erythematosus. Actas Dermosifiliogr 105:18–30
Uppsala Monitoring Center. The use of the WHO-UMC system for standardised case causality assessment. https://www.who.int/medicines/areas/quality_safety/safety_efficacy/WHOcausality_assessment.pdf. Accessed 25 Jan 2022
Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, Janecek E, Domecq C, Greenblatt DJ (1981) A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 30:239–245
Cerqueira A, Seco T, Paiva D, Martins H, Cotter J (2020) Isoniazid-induced lupus: when the cure can be lethal. Cureus 12:7311
Vasoo S (2006) Drug-induced lupus: an update. Lupus 15:757–761
Timmins G, Deretic V (2006) Mechanisms of action of isoniazid. Mol Microbiol 62:1220–1227
Huang YS, Chern HD, Su WJ, Wu JC, Lai SL, Yang SY, Chang FY, Lee SD (2002) Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis. Hepatology 35:883–889
Berning SE, Iseman MD (1997) Rifamycin-induced lupus syndrome. Lancet 349:1521
Fanouriakis A, Kostopoulou M, Alunno A, Aringer M, Bajema I, Boletis JN, Cervera R, Doria A, Gordon C, Govoni M, Houssiau F, Jayne D, Kouloumas M, Kuhn A, Larsen JL, Lerstrøm K, Moroni G, Mosca M, Schneider M, Smolen JS, Svenungsson E, Tesar V, Tincani A, Troldborg A, van Vollenhoven R, Wenzel J, Bertsias G, Boumpas DT (2019) 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Rheum Ann Dis 78:736–745
Hoffman BJ (1945) Sensitivity to sulfadiazine resembling acute disseminated lupus erythematosus. Arch Dermatol Syphilol 51:190–192
Borchers AT, Keen CL, Gershwin ME (2007) Drug-induced lupus. Ann N Y Acad Sci 1108:166–182
He Y, Sawalha AH (2018) Drug-induced lupus erythematosus: an update on drugs and mechanisms. Curr Opin Rheumatol 30:490–497
Alarcon-Segovia D, Fishbein E, Alcala H (1971) Isoniazid acetylation rate and development of antinuclear antibodies upon isoniazid treatment. Arthritis Rheum 14:748–752
Batchelor JR, Welsh KI, Tinoco RM, Dollery CT, Hughes GR, Bernstein R, Ryan P, Naish PF, Aber GM, Bing RF, Russell GI (1980) Hydralazine-induced systemic lupus erythematosus: influence of HLA-DR and sex on susceptibility. Lancet 1:1107–1109
Irizarry-Caro JA, Carmona-Rivera C, Schwartz DM, Khaznadar SS, Kaplan MJ, Grayson PC (2018) Brief report: drugs implicated in systemic autoimmunity modulate neutrophil extracellular trap formation. Arthritis Rheumatol 70:468–474
Hogan JJ, Markowitz GS, Radhakrishnan J (2015) Drug-induced glomerular disease: immune-mediated injury. Clin J Am Soc Nephrol 10:1300–1310
Vaglio A, Grayson PC, Fenaroli P (2018) Drug-induced lupus: traditional and new concepts. Autoimmun Rev 17:912
Luwanda LB, Gamell A (2018) Isoniazid-induced subacute cutaneous lupus erythematosus in an HIV-positive woman: a rare side effect to be aware of with the current expansion of isoniazid preventive therapy. Pan Afr Med J 29:200
Khattri S, Kushawaha A, Dahal K, Lee M, Mobarakai N (2011) Isoniazid (INH)-induced eosinophilic exudative pleural effusion and lupus erythematosus. A clinical reminder of drug side effects. Bull NYU Hosp Jt Dis 69:181–184
Rakotoson JL, Randriamanana D, Rakotomizao JR, Andrianasolo R, Rakotoarivelo R, Andrianarisoa AC (2009) Severe systemic lupus erythematosus induced by isoniazide. Rev Pneumol Clin 65:361–364
Author information
Authors and Affiliations
Contributions
Sanjana Sarangarajan, Sriram Krishnamurthy, Bobbity Deepthi, and Aswini Annadurai managed the patient, reviewed the literature, and drafted the manuscript. Sriram Krishnamurthy reviewed the literature and critically revised the manuscript. Bheemanathi Hanuman Srinivas interpreted the histopathological findings. All authors contributed to the review of literature, drafting of the manuscript, and approved the final version of the manuscript. Sriram Krishnamurthy shall act as the guarantor of the paper.
Corresponding author
Ethics declarations
Conflict of interest
The authors declare no competing interests.
Additional information
Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
This refers to the article that can be found at http://dx.doi.org/10.1007/s00467-022-05435-2.
Rights and permissions
About this article
Cite this article
Sarangarajan, S., Krishnamurthy, S., Deepthi, B. et al. Hematuria and proteinuria in a 14-year-old boy on anti-tubercular treatment: Answers. Pediatr Nephrol 37, 1541–1545 (2022). https://doi.org/10.1007/s00467-022-05462-z
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00467-022-05462-z